Payment overview · 2025
General Payments
$1,683.36
54 reported records · 15 companies
Healthcare provider profile · identity verified
Michael Esantsi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1447260518
Verified facts
What the public records show
CMS Open Payments records show Michael Esantsi, M.D. received $1,683.36 in general payments during 2025 across 54 reported records.
Stryker Corporation accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $530.32 | 31.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $265.09 | 15.8% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $258.10 | 15.3% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $209.33 | 12.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.77 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.47 | 4.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.00 | 3.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.78 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.82 | 2.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.89 | 1.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.82 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.96 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.63 | 1.1% | 1 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $15.33 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.05 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,261.96 | 52 |
| Travel and Lodging | $361.40 | 1 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAKO Normalized: mako |
Device | Stryker Corporation | $530.32 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $258.10 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $247.79 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.07 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $166.62 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.36 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $82.77 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $70.47 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.36 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $51.78 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 103 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 35 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
103 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 77 |
| Gabapentin | Gabapentin | 261 | 76 |
| Ozempic | Semaglutide | 217 | 37 |
| Nifedipine Er | Nifedipine | 201 | 61 |
| Carvedilol | Carvedilol | 200 | 70 |
| Alprazolam | Alprazolam | 180 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 64 |
| Metformin Hcl | Metformin Hcl | 171 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 49 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 154 | 43 |
| Tramadol Hcl | Tramadol Hcl | 151 | 37 |
| Metformin Hcl Er | Metformin Hcl | 149 | 48 |
| Furosemide | Furosemide | 148 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 28 |
| Valsartan | Valsartan | 134 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 40 |
| Losartan Potassium | Losartan Potassium | 125 | 39 |
| Ezetimibe | Ezetimibe | 123 | 39 |
| Simvastatin | Simvastatin | 118 | 34 |
| Farxiga | Dapagliflozin Propanediol | 114 | 35 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 110 | 34 |
| Lisinopril | Lisinopril | 110 | 39 |
| Omeprazole | Omeprazole | 109 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 106 | 34 |
| Methylprednisolone | Methylprednisolone | 105 | 77 |
| Tresiba Flextouch U-200 | Insulin Degludec | 104 | 19 |
| Kerendia | Finerenone | 103 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 100 | 23 |
| Montelukast Sodium | Montelukast Sodium | 92 | 31 |
| Azithromycin | Azithromycin | 88 | 77 |
| Tradjenta | Linagliptin | 87 | 16 |
| Allopurinol | Allopurinol | 85 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 80 | 25 |
| Jardiance | Empagliflozin | 76 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 22 |
| Entresto | Sacubitril/Valsartan | 68 | 21 |
| Glimepiride | Glimepiride | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 12 |
| Folic Acid | Folic Acid | 61 | 19 |
| Sertraline Hcl | Sertraline Hcl | 60 | 21 |
| Mounjaro | Tirzepatide | 59 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 45 |
| Pregabalin | Pregabalin | 58 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 19 |
| Eliquis | Apixaban | 54 | 17 |
| Lorazepam | Lorazepam | 53 | 12 |
| Meloxicam | Meloxicam | 53 | 19 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 22 |
| Trazodone Hcl | Trazodone Hcl | 52 | 16 |
| Xarelto | Rivaroxaban | 51 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 18 |
| Spironolactone | Spironolactone | 49 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Finasteride | Finasteride | 48 | 15 |
| Azelastine Hcl | Azelastine Hcl | 47 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 15 |
| Celecoxib | Celecoxib | 45 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 18 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Prednisone | Prednisone | 40 | 23 |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 11 |
| Famotidine | Famotidine | 32 | 12 |
| Colchicine | Colchicine | 31 | 14 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 18 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,683.36 · 54 records | Stryker Corporation | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KRYSTEXXA, Kerendia, MAKO, MOUNJARO, NOVOSORB BTM, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, Sunosi, Wegovy, YUPELRI, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error